CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 115 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $145,313 | +63.8% | 9,746 | +20.3% | 0.01% | +100.0% |
| Q2 2023 | $88,695 | +366.8% | 8,100 | +36.0% | 0.00% | +200.0% |
| Q1 2022 | $19,000 | -5.0% | 5,958 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $20,000 | -9.1% | 5,958 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $22,000 | -15.4% | 5,958 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $26,000 | -3.7% | 5,958 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $27,000 | -20.6% | 5,958 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $34,000 | -5.6% | 5,958 | +21.1% | 0.00% | 0.0% |
| Q3 2020 | $36,000 | +111.8% | 4,918 | 0.0% | 0.00% | +100.0% |
| Q2 2020 | $17,000 | +142.9% | 4,918 | 0.0% | 0.00% | – |
| Q1 2020 | $7,000 | -30.0% | 4,918 | 0.0% | 0.00% | – |
| Q4 2019 | $10,000 | -60.0% | 4,918 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $25,000 | -28.6% | 4,918 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $35,000 | -46.2% | 4,918 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $65,000 | +66.7% | 4,918 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $39,000 | -27.8% | 4,918 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $54,000 | -18.2% | 4,918 | 0.0% | 0.00% | -33.3% |
| Q2 2018 | $66,000 | – | 4,918 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |